A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer
This is a phase I/II exploratory study to evaluate the efficacy and safety of anlotinib combined with concurrent chemoradiotherapy in the treatment of surgically unresectable stage III non-small cell lung cancer.
Non-small Cell Lung Cancer
DRUG: Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy
Progress free survival (PFS) for phase Ⅱ, PFS defined as the time from first dose of study treatment until the first date of either objective disease progression or death due to any cause., up to 30 months|Maximum Tolerance Dose (MTD) for phaseⅠ, Maximum Tolerance Dose (MTD) is the dose of treatment in the cohort where there are 2 cases of DLT reported.Dose Limiting Toxicity (DLT) is referred to grade 3 non-hematological toxicity or grade 4 hematological toxicity according to NCI CTCAE 5.0 criteria, From enrollment to completion of study. Estimated about 18months
Overall Survival (OS), OS is defined as the time until death due to any cause., From randomization until death (up to 30 months)|Objective Response Rate (ORR), ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1.prior to progression or any further therapy., each 42 days up to intolerance the toxicity or PD (up to30 months)
This is a phase I/II exploratory study to evaluate the efficacy and safety of anlotinib combined with concurrent chemoradiotherapy in the treatment of surgically unresectable stage III non-small cell lung cancer.